VALIANT Study: A Potential New Treatment for Severe Asthma
Trial Objectives
Some people with asthma experience frequent exacerbations, involving swelling or narrowing of the airways, which causes shortness of breath, wheezing and cough. In the national study called VALIANT, researchers are evaluating a new investigational treatment called verekitug to see if it is safe and can effectively reduce inflammation to help asthma patients breathe easier.
Volunteers will be randomly assigned to receive either verekitug or a placebo (a medication containing no active ingredient) every 12 weeks for up to 70 weeks. Every 12 weeks at a clinic visit, volunteers will receive the medications by injection under the skin, complete questionnaires, provide blood and urine samples, and receive physical evaluations that include lung function and lung inflammation testing. Qualified participants have a 75% chance of receiving active drug at one of three doses during the study.
Who Can Participate
Participants who have a diagnosis of asthma must be regularly taking inhaled corticosteroids for at least 3 months at a high dose or medium dose plus another asthma controller medication and have suffered exacerbations requiring additional corticosteroids in the past 12 months.
Age: 18-75 Gender: Any
Estimated Time Commitment
19 visits over up to 70 weeks (1 year and 4 months). Two screening visits will last about 4 hours each, and all other visits will last between 4 and 6 hours.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Upstream Bio, Inc.